NCT00867568 2024-08-06
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Milton S. Hershey Medical Center
Phase 1 Completed
Clinical Trials
12 trialsNCT01505608 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT01933815 2023-02-22
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Cortice Biosciences, Inc.
Phase 1/2 Suspended
NCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01332630 2018-09-20
TPI 287 in Breast Cancer Metastatic to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02047214 2018-01-31
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT01113463 2016-10-31
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00479635 2014-01-22
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT00553813 2014-01-22
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT01340729 2013-04-05
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00113724 2009-06-04
Study of TPI 287 in Patients With Advanced Malignancies
Cortice Biosciences, Inc.
Phase 1 Completed
NCT00256191 2007-10-15
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Cortice Biosciences, Inc.
Phase 1 Completed